Ideas For Profit | Will Sun Pharma's steady India business, US speciality portfolio help it do well in FY21?
In this edition of Ideas For Profit, Moneycontrol's Sakshi Batra decodes Sun Pharma Q1 results and suggests what strategy investors could adopt now.
Hold Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated July 31, 2020.
Earnings Call Transcript - Q1FY21 for Sun Pharmaceuticals
Conference Call with Sun Pharma Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript.
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 01, 2020 for Shanghvi Finance Pvt Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
We refer to our disclosure, dated July 29, 2020, under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding agreement entered into by one of the wholly owned subsidiaries, Taro Pharmaceuticals Inc., of our subsidiary company, Taro Pharmaceutical Industries Ltd., to acquire by way of purchase of all outstanding shares of Aquinox Pharmaceuticals (Canada) Inc. Further to the above, we wish to inform you that our above-referred subsidiary has acquired, on 31st July, 2020, all the shares of Aquinox Pharmaceuticals (Canada) Inc. by making the payment of USD $8.2Mn and complying all requirements. This is for your information and dissemination
Sun Pharma posts 1,656 cr Q1 loss on legal woes in US
The loss was caused by a one-time settlement in a price-fixing case involving Taro.Taro, a Sun Pharma subsidiary, reported settlements and loss contingencies of $478.9 million
Sun Pharma sails through Q1, but the stock may be outpacing profit growth
Sun Pharma's active pharma ingredients (API) segment is proving resilient, with growth of about 20% y-o-y. Even so, the contribution of the API business for captive consumption is rising SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financials for the first quarter ending June 30th, 2020, which we shall be releasing after sending this letter to you. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Approval of Scheme of Amalgamation and Merger of Sun Pharma Global FZE, an indirect wholly owned subsidiary of the Company, into the Company by the Board of Directors at its meeting held on July 31, 2020 For further details refer the attached letter SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2020 And Approval Of Scheme Of Amalgamation And Merger Of Sun Pharma Global FZE, An Indirect Wholly Owned Subsidiary Of The Company, Into The Company
As per letter attached